Accordingly, sulfonylureas are associated with risk of hypoglycemia and weight gain; DPP-4 inhibitors are associated with lower frequency of hypoglycemia and are weight neutral [34–36]. This evidence concerns the gene DPP4 and Hypoglycemia.